Predicting Prognosis in Gastroentero-Pancreatic Neuroendocrine Tumors: An Overview and the Value of Ki-67 Immunostaining
99
Citation
63
Reference
10
Related Paper
Citation Trend
Keywords:
Ki-67
Immunostaining
Proliferation index
Proliferative index
The Ki-67 proliferation index (PI) is a prognostic factor in neuroendocrine tumors (NETs) and defines tumor grade. Analysis of Ki-67 PI requires calculation of Ki-67-positive and Ki-67-negative tumor cells, which is highly subjective. To overcome this, we developed a deep learning-based Ki-67 PI algorithm (KAI) that objectively calculates Ki-67 PI. Our study material consisted of NETs divided into training (n = 39), testing (n = 124), and validation (n = 60) series. All slides were digitized and processed in the Aiforia® Create (Aiforia Technologies, Helsinki, Finland) platform. The ICC between the pathologists and the KAI was 0.89. In 46% of the tumors, the Ki-67 PIs calculated by the pathologists and the KAI were the same. In 12% of the tumors, the Ki-67 PI calculated by the KAI was 1% lower and in 42% of the tumors on average 3% higher. The DL-based Ki-67 PI algorithm yields results similar to human observers. While the algorithm cannot replace the pathologist, it can assist in the laborious Ki-67 PI assessment of NETs. In the future, this approach could be useful in, for example, multi-center clinical trials where objective estimation of Ki-67 PI is crucial.
Ki-67
Proliferation index
Proliferative index
Cite
Citations (15)
Proliferation index
Ultrasound Elastography
Ki-67
Proliferative index
Cite
Citations (2)
This study aimed to clarify the Ki-67 distribution, p53 expression and their relationship with clinico-pathologic features of gastric B cell lymphoma from Northern African population.Twenty paraffin blocks of gastric lymphoma were retrieved from the archival materials of Department of Pathology, Central University Hospital of Sidi Bel Abbes (Western Algeria) from 2007 to 2013. Four µm section specimens were stained by immunohistochemical (IHC) technique with Ki-67 and p53 tumor markers. P values <0.05 were considered statistically significant.Expression of p53 proteins and the mean proliferative index (PI) were compared between high grade gastric B cell lymphomas (DLBCL) and low grade gastric B cell lymphomas (gastric MALTs). p53 overexpression (P=0.007) and a high proliferation index Ki-67 (P=0.001) were significantly associated with gastric DLBCL. We found also a statistically significant correlation between p53 and Ki-67 (P=0.007) but no obvious relationships were found between Ki-67 PI and p53 expression as well as clinico-pathological features (age, sex, location, macroscopic type).The IHC studies of Ki-67 and p53 expression in gastric B cell lymphoma can help in monitoring of patients at risk, and to give suitable treatment and management of patients.
Ki-67
Proliferative index
Proliferation index
Gastric lymphoma
International Prognostic Index
Cite
Citations (12)
The expression of mitosin, a novel proliferation-associated molecule was evaluated immunohistochemically in a consecutive series of 47 patients with primary intracranial benign and atypical meningiomas. Mitosin expression was correlated with proliferation markers Ki-67 (MIB-1), proliferating cell nuclear antigen (PCNA), topoisomerase IIalpha (TopoIIalpha) and mitotic index, as well as with standard clinicopathological parameters and patient outcome. Seven tumors recurred (14.8%) following gross total resection, within a follow-up period ranging from 21 to 108 months (median 60 months). The higher proliferation indices were obtained with mitosin and PCNA and the lower ones with TopoIIalpha. Mitosin labeling index (LI) ranged from 0.1 to 57% (median 3%), with a significant overlapping of values between grades. A significant positive correlation was shown between mitosin LI on the one hand and Ki-67 LI (p < 0.001), or the mitotic index (p = 0.027) on the other. The incidence of recurrence was higher in cases with a mitosin LI higher than 3% (p = 0.048). Univariate analysis disclosed mitosin LI (p = 0.033) along with the mitotic index (p = 0.024) and tumor size (p = 0.028) as significant predictors of shortened recurrence-free survival. In multivariate analysis, the labeling indices of mitosin (p = 0.035) and Ki-67 (p = 0.032), along with tumor size, were shown to provide independent prognostic information, beyond that obtained by standard clinical and pathological parameters. However, as indicated by factor analysis, the prognostic information yielded by mitosin was superior to that provided by the remaining proliferation markers (p = 0.041). We conclude that mitosin immunohistochemical expression, although failing to discriminate between benign and atypical meningiomas, may be of use as a novel cell proliferation marker and as a predictor of tumor recurrence.
Ki-67
Mitotic index
Proliferative index
Univariate analysis
Proliferation index
Proliferation Marker
Cite
Citations (28)
Wilms tumour
Value (mathematics)
Expression (computer science)
Cite
Citations (19)
BackgroundTumor cells have the ability to change the phenotype of inflammatory cells in the tumor environment into protumoral factors. One ofthe mediators produced such as interleukin 17 (IL-17) also plays a role in increasing tumor proliferation and invasion. Similar to IL-17,Ki67 has generally been used as a marker to assess the extent of breast carcinoma proliferation. This is the first study to determinethe relationship of IL-17 expression with Ki67 proliferation index of breast carcinoma patients.MethodsThis is a case series study using 38 paraffin block samples of breast carcinoma patients. The clinicopathological characteristicsdocumented are age, histopathological subtype and grade, TILs (tumor infiltrating lymphocytes) and molecular subtypes. Interleukin17 and Ki67 expressions were assessed using immunohistochemistry examination and data were analysed using the Pearson andSpearman test to assess correlations between the two variables.ResultsGeneral characteristics of the sample in this study were breast cancer patients aged >40 years (73.7%), histopathological subtypesof non-specific invasive carcinoma (84.2%), high tumor rates (78.9%), non-dominant TILs (94.7%) and molecular subtype luminal B(55.3%). There is no relationship between IL-17 expression and Ki67 proliferation index (p 0.72 and OR of 1.417), even though lowerexpression of IL-17 showed a higher Ki67 proliferation index.ConclusionExpression of IL-17 cannot describe the Ki67 proliferation index in breast carcinoma. Studies using another analytical techniques andlarge sample size are suggested to obtain more accurate results.
Proliferation index
Breast carcinoma
Ki-67
Proliferative index
Cite
Citations (0)
INTRODUCTION: The biological behavior of intracranial tumors is associated with the main histopathological characteristics of neoplastic tissue and refers to the presence of mitosis, vascular proliferation, hyperhromasia sails and necrosis. The proliferation of tumor cells can be quantitatively assessed by measuring Ki-67 proliferative (lebeling) index. Various studies have shown the existence of a significant correlation between Ki-67 proliferation index and the biological behavior of intracranial tumor, its grade, tendencies to recurrence and recidive.
HYPOTHESIS: High Ki-67 proliferative index indicates a tendency for recurrence and recidive of radically resected intracranial tumors.
METHODS AND MATERIALS: This study enrolled 40 cases of intracranial tumours which include the benign extrinsic intracranial tumors and malignant intrinsic intracranial tumours. Immunohistochemical analysis was performed for staining of biopsies. Pearson’s chi square test was used to determine statistical correlation between Ki-67 and recurrence and survival of tumour.
RESULTS: We found a statistically significant correlation between the biological behavior of intracranial tumors and Ki67 index, and we determined that the high percentage of Ki-67 index in malignant neoplasms can be grounds for anticipation of their postoperative index.
Keywords: Intracranial tumors, Ki-67, Recurrence, Recidive, Proliferation, Neoplasmas
Ki-67
Proliferation index
Mitotic index
Proliferative index
Positive correlation
Cite
Citations (0)
AIMS: To determine cell proliferation in infiltrating breast carcinomas. METHODS: Using the MIB-1 monoclonal antibody, the proliferation index was measured in paraffin wax sections of 871 breast cancers. The MIB-1 proliferation index was compared with other markers of disease progression: size, lymph node status, histotype, oestrogen and progesterone receptor status, expression of p53 and Neu, and DNA ploidy. All parameters were measured using image analysis. In 347 tumours, the MIB-1 and Ki-67 proliferation indexes were compared. Follow up data were available for 170 cases (median 66.5 months). RESULTS: Of the tumours, 314 (36%) had a high proliferation index. The MIB-1 proliferation index was correlated directly with size, nodal status, overexpression of p53 and Neu, and the DNA index; and inversely with oestrogen and progesterone receptor status. The correlation between MIB-1 and Ki-67 proliferation indexes was statistically significant. In patients with pT1 tumours, a low proliferation index correlated with a longer relapse-free interval and overall survival; node negative patients with a low proliferation index had a longer overall survival. CONCLUSIONS: The MIB-1 proliferation index is a reliable, practical and useful method of measuring proliferative activity and is an important predictor of clinical behaviour.
Proliferation index
Ki-67
Proliferative index
Proliferation Marker
Progesterone receptor
Cite
Citations (65)
Introduction: Many biological markers are used as prognostic and predictive indicators in invasive breast cancers management. Among them, tumour size, grade, patho-morphological subtype, hormone receptors status and HER2 receptor expression in addition to Ki-67 proliferative index. Also, they play a key role in adjuvant treatment decision making. Our aim was to evaluate the association between Ki-67 proliferative index and breast cancer immunological subtype. Material and methods: A total of 515 early invasive patients were enrolled, tumour biological characteristics as histopathological subtype, immune-histo-chemistry (ER,PR,HER2) status and Ki-67 proliferation index values have been collected. The Ki-67 index level of 20%, was used as the cut-off point to differentiate between low and high Ki-67 expression levels. Statistical analysis has been performed using the Chi square test online tool. Results: In this cohort, about 42%, 33%, 7%, and 18% of the cases were grouped as luminal A-like, luminal B-like, HER2 enriched subtype, and triple-negative, respectively. All luminal A-like patients had Ki-67 level less than 20%. About 3% of the cohort, are luminal B-like tumours with Ki-67 level less than 20%, where 30.3% of the patients were luminal B-like tumours with Ki-67 level ≥ 20%. In HER2 enriched subtype, Ki- 67 of < 20% level seen in 1.9% of cases, and Ki-67 levels ≥ 20% was observed in 5.2% of the cases. In the triple-negative group, Ki-67 was 20% or higher in 16% of cases, and only 1.7% of patients had Ki-67 level less than 20%. Conclusion: Luminal A-like tumours were the most frequently encountered subtype, they have low Ki-67 levels and are known to be of a low histological grade tumour, and usually associated with a good prognosis. Also, data indicates that high Ki-67 levels are seen more often in Luminal B-Like breast cancers as well as in triple-negative breast cancers and HER2 enriched tumours.
Ki-67
Proliferation index
Proliferative index
Progesterone receptor
Cite
Citations (4)
Meningiomas are variously benign, atypical or anaplastic neoplasms and can be treated by surgical removal. However, recurrence can be seen even after complete surgical resection in benign meningiomas and some are histologically aggressive. As predictors of recurrence or malignant proliferation some immunohistochemical markers have been used. In this study, we postoperatively identified TfR (transferrin receptor) staining and Ki-67 proliferative index in patients with intracranial meningiomas and evaluated the correlation between these parameters and the recurrence or malignant proliferation. Immunohistochemical techniques (streptavidin-biotin complex) were used to assess the TfR expression and Ki-67 labelling index in 50 surgically removed intracranial meningiomas. Significantly high TfR expression was observed in all types of meningiomas, eight of which recurred. Four cases died because of primary intracranial pathology and one died from uncontrollable epileptic seizures. Ki-67 levels were high in the cases which showed recurrence and showed atypical features. Based on our observations and the results presented above, meningioma patients with TfR score of 3 or higher and high Ki-67 labelling index must be carefully followed up for recurrence, as well as for malignant transformation. Thus, we suggest that TfR and Ki-67 immunostains should be applied routinely in patients with meningiomas.
Ki-67
Proliferative index
Proliferation index
Transferrin receptor
Immunostaining
Surgical pathology
Cite
Citations (7)